These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 26716506)

  • 1. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
    Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
    Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling ErbB2-p130Cas interaction to design new potential anticancer agents.
    Costamagna A; Rossi Sebastiano M; Natalini D; Simoni M; Valabrega G; Defilippi P; Visentin S; Ermondi G; Turco E; Caron G; Cabodi S
    Sci Rep; 2019 Feb; 9(1):3089. PubMed ID: 30816273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
    Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
    Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p130Cas promotes invasiveness of three-dimensional ErbB2-transformed mammary acinar structures by enhanced activation of mTOR/p70S6K and Rac1.
    Tornillo G; Bisaro B; Camacho-Leal Mdel P; Galiè M; Provero P; Di Stefano P; Turco E; Defilippi P; Cabodi S
    Eur J Cell Biol; 2011; 90(2-3):237-48. PubMed ID: 20961652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.
    Nam S; Chang HR; Jung HR; Gim Y; Kim NY; Grailhe R; Seo HR; Park HS; Balch C; Lee J; Park I; Jung SY; Jeong KC; Powis G; Liang H; Lee ES; Ro J; Kim YH
    Cancer Lett; 2015 Jan; 356(2 Pt B):880-90. PubMed ID: 25449779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
    Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
    Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE; Serrero G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
    Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
    Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
    Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients.
    Cheng Y; Tao L; Xu J; Li Q; Yu J; Jin Y; Chen Q; Xu Z; Zou Q; Liu X
    Mol Carcinog; 2014 Sep; 53(9):686-97. PubMed ID: 23681900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2
    D'Alesio C; Bellese G; Gagliani MC; Aiello C; Grasselli E; Marcocci G; Bisio A; Tavella S; Daniele T; Cortese K; Castagnola P
    J Exp Clin Cancer Res; 2017 Nov; 36(1):154. PubMed ID: 29100552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
    He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
    Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X; Wang S; Lee CK; Yang X; Liu B
    Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors.
    Al-Hilli Z; Boughey JC; Hoskin TL; Heins CN; Hieken TJ
    Ann Surg Oncol; 2015 Oct; 22(10):3369-75. PubMed ID: 26202564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
    Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.